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Hypertension is a health problem affecting over 1
billion people worldwide. How the immune sys-
tem gets activated under hypertensive stimuli to
contribute tobloodpressure elevation is a fascinating
enigma. Here we showed a splenic role for placental
growth factor (PlGF), which accounts for the onset
of hypertension, through immune system modula-
tion. PlGF repressed the expression of the protein
Timp3 (tissue inhibitor of metalloproteinases 3),
through the transcriptional Sirt1-p53 axis. Timp3
repression allowed costimulation of T cells and their
deployment toward classical organs involved in hy-
pertension.We showed that the spleen is an essential
organ for the development of hypertension through
a noradrenergic drive mediated by the celiac gan-
glion efferent. Overall, we demonstrate that PlGF
mediates the neuroimmune interaction in the spleen,
organizing a unique and nonredundant response that
allows the onset of hypertension.
INTRODUCTION
Hypertension is a leading cause ofmorbidity andmortality world-
wide, being the major risk factor for stroke, heart failure, and
kidney diseases (Coffman, 2011; Chobanian, 2009). Although
several therapeutic strategies have been developed against
the main components involved in blood pressure (BP) homeo-
stasis (i.e., vasculature, kidney, autonomic nervous system),
the prevalence of uncontrolled hypertension continues to rise
(Lawes et al., 2008) and in the majority of the cases the causes
of BP increase are still unknown. Mounting evidence suggests
that novel players also contribute to the development of hyper-
tensive disease such as components of the innate and adaptive
immune systems (Harrison, 2013; Crowley et al., 2005; Madhur
and Harrison, 2012). For example, angiotensin II (AngII), one of
the main factors influencing BP levels, has been described as
amajor trigger of inflammation in several tissues (e.g., resistanceIvessels and kidney) involved in BP regulation. However, inflam-
mation and immunity have been mostly studied as a part of the
injury evoked by hypertension and atherosclerosis (Packard
et al., 2009; Kim and Iwao, 2000).
A previous observation showed that mice born with the
genetic disease aplasia of the thymus manifest protection
in developing hypertension, suggesting the existence of a
key role of adaptive immune system (Svendsen, 1976). More
recently, an emerging area of investigation revealed that im-
mune cells are crucial players in the onset of hypertension, infil-
trating vessel walls and kidneys of hypertensive animals (Bush
et al., 2000; Ishibashi et al., 2004; Wenzel et al., 2011) and that
mice devoid of lymphocytes also manifest protection in devel-
oping AngII-induced hypertension (Guzik et al., 2007). Never-
theless, it is unclear how T cells are activated to contribute
to hypertension. Among the manifold inflammatory mediators,
placental growth factor (PlGF), belonging to a family of vascular
endothelial growth factor (VEGF)-related angiogenic factors,
caught our attention given its role of ‘‘angiogenic cytokine’’
and its expression by cells of both the cardiovascular and the
immune system (De Falco et al., 2002; Carnevale and Lembo,
2012). Indeed, PlGF participates in pathological angiogenesis
in contexts such as tumor environment and wound healing (Lut-
tun et al., 2002; Van de Veire et al., 2010; Bais et al., 2010) and,
at the same time, has a specific role in macrophage mobiliza-
tion (Perelman et al., 2003; Pipp et al., 2003; Carnevale et al.,
2011). Moreover, the molecular pathway related to PlGF and
sFlt1, a soluble form of its main receptor and its endogenous
inhibitor, has been classically associated to pregnancy-related
hypertension (Steinberg et al., 2009). Finally, it has also been
demonstrated that PlGF is secreted in vascular cells in
response to AngII (Pan et al., 2010). Thus, in the present
work we aimed to explore the role of PlGF in hypertension.
We found that PlGF has a crucial role for the onset of hyperten-
sion, played in the splenic immune system. In particular, we
unveiled that PlGF mediates a neuroimmune interaction be-
tween the sympathetic nervous system and the splenic immune
system, which is activated during hypertensive challenges.
In the end, we dissected the molecular mechanism regulated
by PlGF in the spleen, responsible for the costimulation
of T cells, which act as the final effectors in target organs of
hypertension.mmunity 41, 737–752, November 20, 2014 ª2014 Elsevier Inc. 737
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Onset of Hypertension Requires PlGF
InWTmice, chronic AngII infusion produced a progressive rise in
blood pressure (BP) when measured either by radiotelemetry
(Figure 1A) or tail cuff (Figures 1B–1D), becoming significant
starting at 4 days after a prehypertensive phase, referred as
pre-HTN (Figures 1B–1D). Infusion of vehicle alone had no effect
on arterial pressure (Figures 1A–1D). This hypertensive response
was completely abolished in mice with genetic deletion of PlGF
(encoded by Pgf) (Figures 1A–1D). In contrast, the heart rate
was similar between wild-type (WT) and PlGF-deficient mice
both in basal condition (605 ± 18 versus 634 ± 12 bpm, n.s.)
and after chronic AngII (574 ± 22 versus 616 ± 18 bpm, n.s.).
Activation of the renin-angiotensin system through stimulation
of type 1 angiotensin receptor is not only a key regulator of BP
elevation but also of end-organ damage (Packard et al., 2009;
Gurley et al., 2011; Li et al., 2011). Indeed, target organ injury re-
sults from both BP-dependent biomechanical challenge and BP-
independent hormonal effects. In particular, AngII can directly
induce inflammation and fibrosis, thereby contributing to target
organ damage. Whereas the echocardiographic analysis after
chronic AngII showed the typical cardiac hypertrophic response
in WT mice, PlGF-deficient mice were protected from cardiac
remodeling (see Table S1 available online). Because chronic
kidney disease is also frequently associated with hypertension,
we analyzed Masson trichrome and Sirius Red-stained sections
of kidney from 4 weeks AngII-infused WT mice, revealing signif-
icant fibrosis in both glomeruli and interstitial areas between
tubules (Figures S1A and S1B, respectively). In contrast, PlGF-
deficient mice were protected from chronic AngII-induced renal
damage, as shown by the lack of tissue fibrosis (Figures S1A
and S1B). Vascular hypertrophic remodeling has been another
recurrent finding in both experimental and clinical hypertension.
The AngII-induced increase in wall thickness of thoracic aorta,
observed in WT mice, was significantly blunted in the aortas
from PlGF-deficient mice (Figure S1C). Finally, hypertension
also affects vascular contractile response to agonists. In partic-
ular, a higher vasoconstriction was induced by phenylephrine in
resistance arteries from WT mice infused with AngII for 4 weeks
(Figure S1D). In contrast, resistance arteries isolated from AngII-
infused PlGF-deficient mice showed an unaltered response to
phenylephrine, comparable to that of vehicle-treated mice (Fig-
ure S1D). Thus, these results indicate that the presence of
PlGF is required for the typical BP increase to chronic infusion
of AngII, given that PlGF-deficient mice show protection from
developing hypertension and its related target organ damage.Figure 1. Onset of Chronic Hypertension and T Cell Vascular Infiltratio
(A) Telemetric BP monitoring after 4 weeks of AngII in PlGF-deficient mice, indica
mean ± SEM values of SBP and DBP.
(B–D) Noninvasive tail cuff monitoring of BP response to chronic AngII, in PlGF KO
groups; n = 8 for vehicle-treated groups. Panels represent mean ± SEM values o
(E and F) Immunostaining and quantitative analysis of CD8 (left panels)- and CD4
from 4weeks AngII PlGF KO versusWTmice (and respective vehicle infusedmice)
WT-AngII versus WT-veh; ###p < 0.001 PlGF KO-AngII versus WT-AngII (two-wa
(G) FMT-CT of in vivo inflammatory activity (MMPsense) in kidneys from 4 week
vehicle-treated groups. Fluorochrome concentration is shown in kidneys, on t
(fluorescence intensity) of MMPsense. ***p < 0.001 PlGF KO AngII versus PlGF W
IImmune System Activation to AngII Needs PlGF
In order to investigate the molecular mechanism responsible for
the protection from hypertension, observed in PlGF-deficient
mice, we first looked for direct vascular effects of the growth fac-
tor. In particular, given that we found increased PlGF amounts in
vascular tissues (Figure S1E), we stimulated resistance arteries
isolated from WT mice with increasing doses of recombinant
PlGF, finding no vasoconstricting effect (Figure S1F) but rather
a mild vasodilating one (Figure S1F). The same vessels showed
typical vasoconstriction and vasodilation when tested with
increasing doses of typical agonists, like phenylephrine and
acetylcholine, respectively (Figure S1F). To further exclude a
direct vascular effect of PlGF in the hypertensive response
induced by AngII, we tested the in vivo acute BP responses to
increasing doses of AngII, which are typically vasoactive depen-
dent (Figure 1G). Both WT and PlGF-deficient mice showed a
comparable increase in systolic (SBP) and diastolic blood pres-
sure (DBP) in the acute response to AngII infused directly in the
vasculature (Figure S1G), thus suggesting that the lack of PlGF
affects AngII-induced mechanisms during the chronic onset of
hypertensive condition.
Considering that PlGF is an ‘‘angiogenic cytokine,’’ capable
of finely regulating inflammation and immune cells besides its
angiogenic effects, we hypothesized that hypertensive stimuli,
known to recruit adaptive immune cells, could exploit PlGF to
modulate some immune function. It has been demonstrated
that activated T cells contribute to vascular remodeling directly
on blood vessels via effects of the cytokines produced, or indi-
rectly by actions on the kidney (Harrison et al., 2010). Clearly,
chronic AngII infusion induced a marked infiltration of CD8+
and CD4+ T cells in vessels and kidneys of WT mice (Figures
1E and 1F). Conversely, after 4 weeks of AngII infusion, PlGF-
deficient vessels and kidneys were devoid of T cell infiltration
(Figures 1E and 1F). Moreover, noninvasive fluorescence molec-
ular tomography–CT imaging (FMT-CT) with inflammation-activ-
able sensors (MMPsense), further confirmed the protection from
the activation of inflammation or immune system in target
organs, as shown by absence of fluorescent pool of probes in
kidneys of PlGF-deficient mice after 4 weeks of AngII infusion,
as compared to WT (Figure 1G).
To determine whether the protection of PlGF-deficient mice
via suppression of T cell infiltration during hypertension had a
causal role or was merely a consequence of the lack of BP
increase, we analyzed vessels and kidneys early after AngII infu-
sion, in the pre-HTN phase, i.e., at 3 days, before stable BP
increase. Although no sign of renal damage was evident in pre-
HTN mice, as showed by Masson trichrome and Sirius Redn in Target Organs Induced by AngII Requires PlGF
ted herein as PlGF KO (n = 6) versus WT mice (n = 4). Floating bars represent
versus WTmice (and respective vehicle infused mice). n = 10 for AngII-treated
f SBP (B), DBP (C), and MAP (D).
(right panels)-positive cells in aortas (upper panels) and kidneys (lower panels)
. n = 6 for AngII-treated groups and n = 4 for vehicle-treated groups. ***p < 0.001
y ANOVA followed by Bonferroni’s post hoc test).
s AngII PlGF KO versus WT mice. n = 6 for AngII-treated groups and n = 4 for
he basis of CT-derived anatomy. Graph showing quantitative analysis of FI
T AngII (t test). All data are shown as mean ± SEM.
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CD4+ T cells, positive for the early activation marker CD69 and
the homing antigen CD44, were already infiltrated in vessels
and kidneys (Figures 2A–2C and Figures S2C–S2H). PlGF-defi-
cient mice showed protection from immune cell infiltration, as
compared to pre-HTN WT mice, thus suggesting a mechanistic
role of PlGF in immune-system activation during the early devel-
opment of hypertension. At same time, CD3 cells in the area of
splenic white pulp (WP) were increased in pre-HTN AngII PlGF-
deficient as compared toWTmice (Figures 3A and 3B), suggest-
ing that the lack of T cell infiltration in target organs could be due
to impaired T cells activation and egress from splenic reservoir
into circulation toward inflamed target tissues. Thus, concurrent
results indicate that, the protectionmanifested by PlGF-deficient
mice in response to AngII induced hypertension, could be
ascribed to a role in modulating the splenic immune system
more than a more typical vascular action.
A Neuroimmune Interaction Mediates PlGF Release in
Hypertension
Lymphocytes homing to target organs during hypertension has
been shown to be a crucial step for both raising in BP and end
organ damage (Guzik et al., 2007), suggesting that the hyperten-
sive challenge involves innate and adaptive immune responses.
In the spleen, the innate and adaptive immune cells are orga-
nized to allow rapid sensing of challenges and consequently,
molecular interactions that lead to differentiation and migration
of T cells (Mueller and Germain, 2009). We found that, besides
the vascular production, PlGF is induced in the pre-HTN phase
of AngII infusion in the stromal tissue of the spleen along
the marginal zone (MZ), as evidenced in the costaining with
CD169 and ERTR7, identifying metallophilic marginal zone mac-
rophages and fibroblast reticular cells respectively (Figure 3C
and Figures S3A and S3B).
The central nervous system (CNS) plays a pivotal role in AngII-
induced hypertension through peripheral sympathetic activation
(Marvar et al., 2010). It has been reported that selective removal
of sympathetic innervation to the splanchnic district, obtained
by celiac ganglionectomy (CGX), markedly attenuated AngII-
induced hypertension (King et al., 2007). Considering that the
spleen is the splanchnic organ most densely innervated by
the sympathetic nervous system (SNS), we hypothesized that
the early induction of splenic PlGF upon AngII infusion could
be mediated by a neuroimmune interaction. Indeed, amounts
of tyrosine hydroxylase (TH), the rate-limiting enzyme for pro-
duction of noradrenaline (NA) in sympathetic fibers (Dutta
et al., 2012; Zigmond and Ben-Ari, 1977), and NA itself,
increased in both WT and PlGF-deficient mice in pre-HTN AngII,
as evidenced by CD169 and TH double staining (Figure 3D) andFigure 2. PlGF Is Necessary for Early T Cell Homing after AngII
(A and B) Outline of gating strategy for identification of CD4 and CD8 T cells pos
aortas. Sample flow-cytometric analyses of single cell suspensions from whole a
leukocytes based on CD45 expression was performed, before analyzing the num
CD45-CD8-positive cells was performed to analyze the number of activated ce
isolated from kidney homogenates.
(C and D) Flow cytometric analysis of kidneys and aortas. Quantification shown as
marked with CD44 and CD69 antigens. n = 6 per each group. *p < 0.05 and **p <
WT-AngII (two-way ANOVA followed by Bonferroni’s post hoc test). All data are
Iquantitative ELISA of NA (Figure S3C). These results were
suggestive of a higher sympathetic tone upon AngII challenge,
despite the genotype. When we performed CGX in WT mice to
look at splenic PlGF we found a marked reduction (Figure 3C
and Figures S3A and S3B) thus demonstrating that PlGF is acti-
vated by Ang-II induced SNS overactivity. The efficacy of sym-
pathetic splenic denervation obtained with CGX surgery was
confirmed bymeasuring the levels of NA in splenic homogenates
(Figure S3C).
In order to provide direct evidence that the sympathetic drive
in the spleen is necessary for T cell recruitment into hypertension
target organs, we evaluated the presence of infiltrating cells in
the aortas and kidneys of CGXmice compared to the sham oper-
ated controls, in AngII pre-HTN (Figures S3D and S3E). The sym-
pathetic denervation significantly reduced the number of both
CD4+ and CD8+ T cells infiltrating in the aortas (Figure S3D)
and in kidneys (Figure S3E) of AngII pre-HTNmice. These results
show that at this time the effect is also due to a mechanistic role
of splenic nerve and not merely to the lack of BP rising, later
observed in this experimental condition. Thus, we highlight a
role for PlGF, able to mediate a neuroimmune interaction during
hypertensive challenges, being activated by a sympathetic drive,
conducted through the celiac ganglion.
Splenic PlGF Is Essential for Hypertension
In order to track unambiguously the fate of T cells from the spleen
to the target tissues during hypertension, we studied CD45.2
mice that were splenectomized and given CD45.1 spleens by
transplantation and then infused with AngII to induce hyperten-
sion. Surgical procedures, control of vitality of transplanted
organs, and regrowth of sympathetic innervation are shown in
Figures 4A–4D. As shown in Figures 4E and 4F, we observed
increased numbers of donor (CD45.1) T cells in aortas and kid-
neys of AngII pre-HTN animals, demonstrating that the immune
cells infiltrating target organs in hypertension are of splenic
origin.
Then we sought to identify whether the splenic immune reser-
voir could be necessary for the establishment of a hypertensive
response to AngII. When we challenged splenectomized mice
with AngII, they showed a clear protection from BP elevation
(Figure 4G) and T cells infiltration (Figures S4A and S4B), demon-
strating an essential role of the spleen in hypertension. Interest-
ingly, recent works highlighted the fact that a challenge like
myocardial infarction elicits splenic innate immunity, thus sug-
gesting the existence of a pathophysiological link among the
cardiovascular and immune system (Swirski et al., 2009).
To define unambiguously the role of PlGF in the onset of
hypertension through modulation of the immune system in the
splenic reservoir, we studied chimericmice, generated by spleenitive for the early activation marker CD69 and the homing marker CD44 in the
ortas from pre-HTN WT (A) and PlGF-deficient (PlGF KO) mice (B). Gating on
ber of CD4- and CD8-positive cells. Gating on CD45-CD4-positive cells and on
lls (CD69+ and CD44+). The same strategy of analysis was applied for T cells
absolute numbers of total CD4+ and CD8+ T cells and amount of activated cells
0.01 WT-AngII versus WT-veh; #p < 0.05 and ##p < 0.01 PlGF KO-AngII versus
shown as mean ± SEM.
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Chimeric mice were then subjected to chronic AngII infusion. In
WT mice that received PlGF-deficient spleens, AngII failed to
raise BP (Figure 4H) and to mobilize T cells into target tissues
as shown by the absence of both CD8+ and CD4+ T cell infiltrate
(Figures S4C and S4D). When we performed the reverse exper-
iment by transplanting WT spleens into splenectomized PlGF-
deficient mice, AngII was able to induce hypertension (Figure 4H)
and T cell mobilization into target tissues (Figures S4C and S4D).
As a control of these experiments, both WT and PlGF-deficient
splenectomized mice received spleens of their same genotype,
showing comparable results to nonoperated mice of respective
genotypes (Figure 4H and Figures S4C and S4D). Thus, our find-
ings obtained in CD45.1 into CD45.2 chimericmice show that the
spleen is a necessary organ in the development of hypertension,
given that T cells homing into target tissues come from the donor
spleen. Moreover, at the molecular level, the PlGF-deficient into
WT chimeric mice (and vice versa) demonstrate that the expres-
sion of PlGF in the spleen is crucial for mobilizing T cells into
target tissues and for the onset of hypertension.
PlGF Modulates Timp3 to Check T Cell Costimulation
PlGF is expressed in the MZ of the spleen, in a network of FRCs,
identified by the ERTR7 and CD169 antigens (Figure 3C and Fig-
ure S3A). This zone of the spleen is particularly enriched in mac-
rophages and dendritic cells with a highly specialized phenotype
(Mueller and Germain, 2009) acting as antigen-presenting cells
(APCs) and directly or indirectly activating T cells. So far, it is un-
known how hypertensive stimuli are able to condition and orga-
nize adaptive immune responses in the spleen. Classically this
happenswhen, after antigen uptake, APCs undergo amaturation
process characterized by an increased surface expression of
major histocompatibility complex II (MHCII) and the B7 ligands,
CD80 and CD86 (Song et al., 2008). Interestingly, it has been
demonstrated that the AngII hypertensive challenge is able to
increase the percentage of cells expressing CD86 in the splenic
reservoir, while the number of cells expressing CD80 and MHCII
remained unchanged (Vinh et al., 2010). However, how hyper-
tensive stimuli could check the costimulation axis of immune
system is unknown.
We found that early upon AngII stimulation, the lack of PlGF
significantly protected from CD86 increase in the MZ, as evi-
denced by the costaining with CD169 (Figure 5A). Flow-cytome-
try analysis evaluating coexpression of CD86 with CD11b,
mainly recognizing monocytes, and CD68-F4/80 for macro-
phages, in a fraction of monocytes and macrophages enriched
from total splenocytes, showed a significant increase of CD86
in macrophages after AngII stimulation (Figures 4B and 4C andFigure 3. PlGF Is Required for Splenic T Cell Egression and Its Releas
(A) Immunostaining of spleen from pre-HTN PlGF-deficient (indicated as PlGF KO
pulp (WP), as delineated by counterstaining with B220 antigen recognizing red p
(B) Flow-cytometry analysis of CD8+ and CD4+ in splenocytes. Plots are represen
with PE and PerCP, respectively and gated on APC-CD3+ cells. n = 6 per group.
(two-way ANOVA followed by Bonferroni’s post hoc test). All data are shown as
(C) Immunostaining of spleen from pre-HTN PlGF KO versus WT mice (and respe
CD169 antibody. Images are representative of n = 6 for AngII-treated groups an
(D) Immunostaining for TH in splenic MZ, showing a comparable increase in PlGF
mice, obtained through CGX and documented by the loss of TH staining, hampe
IFigures S5A and S5B). As evidenced in representative plots
and relative quantifications (Figures 4B and 4C and Figures
S5A and S5B), the absence of PlGF significantly hampered the
expression of CD86 in splenic macrophages, as shown by
reduced amount of CD86+CD68+ cells. These data were further
sustained by the reduced expression of CD86+ macrophages
localized in CD68 positive area of PlGF-deficient MZ obtained
by immunofluorescence (Figure S5C).
We then established a localized gene knockdown experiment
of CD86 in the spleen. As shown in Figure 5D, we delivered an
antiCD86 siRNA directly into the splenic artery and we evaluated
the efficacy of knockdown by flow cytometry (Figures S5D and
S5E). Thereafter, we looked at the T cells infiltrating into the
target tissues upon AngII infusion, finding a significant reduction
of both CD4- and CD8-positive cells (Figures 5E and 5F), thus
demonstrating that the activation of splenic CD86 upon AngII
challenge is necessary to allow T cells egress.
The modulation of tissue proteins of inflammation is able to
condition APCs and consequently activate T cells (Shao et al.,
2012). In particular, it has been shown that one of these proteins,
the tissue inhibitor of metalloproteinases 3 (Timp3), is a key tis-
sue factor for suppression of costimulation processes (Shao
et al., 2012). We have recently found that PlGF has a crucial
role in keeping the expression of Timp3 downregulated in car-
diac tissue (Carnevale et al., 2011). Thus, we investigated
whether the presence of PlGF could be crucial to mediate the
crosstalk among innate-adaptive immunity during AngII chal-
lenge and depending on costimulation through a checkpoint of
Timp3 expression. We found that, while in WT mice AngII did
not modify Timp3 expression in the splenic MZ (Figures 6A and
6B), PlGF-deficient mice displayed a strong upregulation of
Timp3 expression (Figures 6A and 6B), as evidenced by the
colocalization with CD169 and CD68macrophages. Conversely,
no other splenic zones showed this pattern of Timp3 regulation
(Figure S6A). To disclose whether the upregulation of Timp3
occurring in absence of PlGF is relevant for hypertension, we
used transgenic mice overexpressing Timp3 under the promoter
of CD68+ (MacT3 transgenic mice) (Casagrande et al., 2012),
inducing Timp3 in splenic macrophages positive for CD169
and CD68 already in basal conditions and further increased by
AngII (Figures S6B and S6C). Moreover, we found that the over-
expression of Timp3 in CD68+ macrophages hampered the acti-
vation of CD86+ in the same CD68+ cells upon AngII infusion, as
evidenced by immunofluorescence (Figure 6C) and flow cytom-
etry in a fraction of macrophages enriched from total spleno-
cytes (Figures 6D and 6E and Figures S6D and S6E). When
challenged with AngII, MacT3 transgenic mice were protected
from development of hypertension (Figure 7A) and T celle in the Spleen Is Mediated by a Neuroimmune Interaction
) versus WT mice (and respective vehicle-infused mice), showing CD3+ white
ulp. n = 6 for AngII-treated groups; n = 4 for vehicle-treated groups.
tative of n = 6 for group. Quantitative analysis showing absolute T cells labeled
*p < 0.05 WT-AngII versus WT-veh; #p < 0.05 PlGF KO-AngII versus WT-AngII
mean ± SEM.
ctive vehicle-infused mice), showing PlGF (green) in the MZ, labeled with anti-
d n = 4 for vehicle-treated groups.
KO andWTmice, after AngII infusion. Selective sympathetic denervation in WT
red the expression of PlGF in the MZ (C).
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Figure 4. An Essential Role of the Spleen in Hypertension Is Mediated by PlGF
(A) Color Doppler analysis in transplanted spleen and sham operated mice, showing blood vessels within the transplanted or native organ.
(B) TH staining in sections from spleen after 4 weeks from transplantation, documenting regrowth of SNS innervation.
(C) Celiac ganglion neurons labeled with a retrograde fluorescent neurotracer, injected in the splenic parenchyma 4 weeks after spleen transplantation. Celiac
ganglions were analyzed 1 week after neurotracer injection.
(D) Cartoon representing chimeric mice obtained after spleen transplantation.
(E) Accumulation of T cells originating exclusively from the donor spleen (CD45.1) as measured by flow cytometry. Dot plots (CD45.1 versus CD45.2) of T cells
gated on total leukocytes population in aorta and kidney from AngII pre-HTN mice (sham operated mice are shown as control).
(F) BP response to chronic AngII, in splenectomizedWT versus shammice (and respective vehicle infused mice). n = 6 per group. Panels represent mean ± SEM
values of SBP, DBP, and MAP. ***p < 0.001 WT AngII versus WT-veh; ###p < 0.001 WT-AngII-spleen versus WT-AngII (repeated-measures two-way ANOVA
followed by Bonferroni’s post hoc test).
(G) BP response to chronic AngII, in different groups of chimeric mice, obtained by spleen transplantation among PlGF-deficient (PlGF KO) mice and WT mice.
n = 3 per group. Panels represent mean ± SEM values of SBP, DBP, and MAP. ***p < 0.001 WT in WT versus KO in KO; ###p < 0.001 WT in KO versus KO in WT
(repeated-measures two-way ANOVA followed by Bonferroni’s post hoc test).
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type matching the one of PlGF-deficient mice. Thus, with these
results, we show that PlGF is able to regulate the activation of
CD86-dependent costimulation pathway, one of the key mecha-
nisms that are needed for T cells activation. Moreover, we found
that this control is exerted through the regulation of Timp3
expression in macrophages.
PlGF Mediates an Epigenetic Checkpoint of Immune
System Activation through the Sirt1-p53 Axis
Timp3 is mostly known as a tumor suppressor gene and, as
such, it is mainly regulated by transcriptional repression through
epigenetic mechanisms not fully understood. Evidence suggests
that promoter hypermethylation might not be the predominant
epigenetic alteration and that transcriptional repression regu-
lated by p53 might have a predominant role at least in tumors
(Loging and Reisman, 1999) where both Timp3 and p53 play
crucial roles. Considering that both this pathway and PlGF itself
have been classically linked to cancer, we hypothesized that the
PlGF-dependent regulation of Timp3 could be related to p53 in
hypertension. To clarify this issue, we used a chromatin immuno-
precipitation (ChIP) assay to check whether the presence of
PlGF is a determinant factor for p53 binding on its element
response in Timp3 promoter and its consequent transcriptional
repression. While Timp3 is detectable in p53-bound chromatin
from WT splenocytes upon AngII, PlGF-deficient splenocytes
showed a clear reduction of Timp3 sequence linked to p53
(Figure 7B). Interestingly, the latter is well known to regulate tran-
scription of genes that harbor its response element in the pro-
moter region, depending on its acetylation status (Loging and
Reisman, 1999). Because p53 has been identified as a bona
fide substrate of Sirt1 deacetylase activity (Vaziri et al., 2001),
we looked at Sirt1 in our experimental setting. We found that,
in contrast to what observed in WT mice where Sirt1 expression
remained unmodified upon AngII, PlGF-deficient mice showed
that this deacetylase was significantly increased in the MZ of
the spleen (Figure 7C), but not in other splenic districts (Fig-
ure S7G). To prove that the control on splenic expression of
Timp3, which conditions the milieu necessary for T cells activa-
tion and egression in hypertension, is exerted by PlGF through a
Sirt1-p53 axis, we performed an in vivo experiment of both phar-
macological inhibition and genetic silencing of Sirt1 (Figures 7D
and 7E and Figure S7H). PlGF-deficient mice, after both the
chronic administration of the selective Sirt1 inhibitor Ex-527
and the genetic knockdown of Sirt1 obtained by local splenic
infusion of a Sirt1 siRNA (Figure S7H), allowed restoration of
increased BP response to AngII infusion, thus achieving a hyper-
tensive response to levels comparable to that observed in PlGF
WT mice (Figures 7D and 7E). With this set of experiments, we
have found that PlGF regulates the expression of Timp3, needed
as a checkpoint of T cells costimulation in hypertension, through
a transcriptional control exerted by the Sirt1-p53 axis.
DISCUSSION
Here we showed an unprecedented role of PlGF in the spleen,
orchestrating the immune response to the SNS activated by
the hypertensive challenge. Our study brought to light both
how important the neuroimmune drive in the spleen is in the gen-Iesis of hypertension and, at same time, showed that PlGF is
the molecular pathway recruited in the spleen to control BP
changes.
Twomain findings have guided our study. First, we have found
that PlGF-deficient mice manifest protection from AngII-induced
hypertension, one of the most common experimental models of
hypertension, given that in the human pathology, the use of
drugs that target AngII is still one of the main therapeutic ap-
proaches used in clinical practice. Second, we have demon-
strated an unprecedented and unexpected role of the splenic
neuroimmune interaction in hypertension, finding that CGX
prevents PlGF induction in theMZ of splenic reservoir upon AngII
challenge, and that immune cells infiltrating target organs of
hypertension originate from the spleen. Consistent with the latter
point, splenectomized mice are protected from AngII-induced
BP increase. Strikingly, when we generated chimeric mice by
spleen transplantation (PlGF-deficient spleen in WT background
and vice versa), we demonstrated that splenic PlGF is indispens-
able for the onset of hypertension.
We have found that PlGF is crucial to allow T cell costimulation
via CD86 and their consequent egress for the deployment to-
ward vasculature of target organs, a hallmark of hypertension.
In particular, this effect is exerted by an epigenetic modulation
of Timp3 expression, obtained by controlling p53 repressor ac-
tivity on its promoter that strongly depends on the Sirt1 deacety-
lase activity.
PlGF has been mainly associated to vascular effects linked
to direct vasodilation or to modulation of vascular resistance
through binding with the soluble form of its cognate receptor
(sFlt1). Thus, our data on the role of PlGF in modulating immunity
to establish hypertensionwould seemat oddswith expectations.
However, the effects of PlGF on blood pressure regulation
described in the present work rely on completely different
mechanisms of action. Themodel of AngII-induced hypertension
acutely involves effects that depend on direct regulation of
vascular function (where PlGF seems to not to be involved or
might even be involved in an opposite way). However, chronic
hypertensive pathology induced by AngII infusion is more com-
plex, including the regulation of blood pressure and vascular
function, where the immune system plays a crucial role (Guzik
et al., 2007). Our data show that PlGF is one of the central molec-
ular players in the chronic phase of the response. On account of
this, we reasoned that PlGF has dual effects. On the one hand it
has vascular functions that could induce both angiogenic and
vasorelaxant effects. On the other hand, PlGF appears as a crit-
ical regulator of immune functions, responsible for the activa-
tion of T cells in hypertension, a phenomenon well known to be
crucial for establishment of chronic hypertension. This could
also reconcile the fact that sFlt1, which would lower PlGF avail-
ability, has been classically associated to hypertension and prin-
cipally to preeclampsia.
An important implication of our data is the therapeutic poten-
tial. PlGF appears as an appealing molecular target for therapeu-
tic implications because clinical tools to target this pathway
already exist (Van de Veire et al., 2010; Bais et al., 2010). In the
last years, anti-PlGF monoclonal antibodies have been devel-
oped as a strategy to slow tumor growth and for age-related
macular degeneration. The ongoing clinical trials testing
humanized monoclonal antibodies directed to PlGF provide themmunity 41, 737–752, November 20, 2014 ª2014 Elsevier Inc. 745
Figure 5. Splenic PlGF Is Required for the Expression of Macrophage CD86 upon AngII, a Crucial Step in the Activation and Egress of T Cells
(A) Immunostaining of spleen from pre-HTN WT mice versus PlGF-deficient (indicated as PlGF KO) and CGX (and respective vehicle infused mice), using anti-
CD86 (green) and anti-CD169 (red) antibodies. Images are representative of n = 6 mice per group.
(B and C) Flow cytometric analysis in a fraction of monocytes/macrophages enriched from total splenocytes. Quantitative analysis in (B) showing the percentage
of CD86 expression in different fractions of monocytes/macrophages from the enriched population: CD11b+, F4/80+, and CD68+ cells. n = 6 per group. **p < 0.01
(legend continued on next page)
Immunity
Splenic PlGF: A Neuroimmune Dealing in Hypertension
746 Immunity 41, 737–752, November 20, 2014 ª2014 Elsevier Inc.
Immunity
Splenic PlGF: A Neuroimmune Dealing in Hypertensionpossibility to target it in hypertension too. There is a pressing
need for new treatments to reach satisfactory control rates in
the substantial proportion of people with hypertension who do
not achieve the BP target levels recommended by current guide-
lines. At same time, our findings raise an intriguing question
about the effect of PlGF inhibition in cancer, concerning its
dependence on the previously unknown capability to exert an
epigenetic modulation of p53-Timp3 axis, which is well known
to play a crucial role also in tumor growth.
EXPERIMENTAL PROCEDURES
Animals
All animal handling and experimental procedures were performed according
to European Communities guidelines (EC Council Directive 2010/63) and the
Italian legislation on animal experimentation (Decreto L.vo 116/92). The proto-
col was approved by the Italian Ministry of Health (Permit number 58/2012-B).
Mice of 12–15 weeks were used in all experiments. PlGF-deficient mice were
backcrossed for 11 generations in C57Bl/6J mice from the original strain in
50% 129Sv/ 50% Swiss mice (Gigante et al., 2006). MacT3 transgenic mice
were generated as described elsewhere and backcrossed with C57Bl/6J
(Casagrande et al., 2012). WT mice with the same genetic background
(C57Bl6/J) served as control in both cases. B6.SJL-PtprcaPep3b/BoyJ
(CD45.1+) were used for spleen transplantation experiments.
According to our experience and current literature on the same experimental
models (Guzik et al., 2007; Swirski et al., 2009; Vinh et al., 2010; Wenzel et al.,
2011; Carnevale et al., 2012), the number of animals in each setting used was
enough to determinewhether therewas a significant difference among groups,
as tested by the software PS3.0
Angiotensin II (0.5 mg/kg/day) or vehicle (NaCl 0.9%) were delivered
subcutaneously with osmotic minipumps (model 1007D, ALZET). At day 3 or
28, accordingly to experimental design, mice were euthanized by overdose
of sodium pentobarbital anesthesia.
Celiac Ganglionectomy
In mice anesthetized with ketamine-xylazine, the celiac ganglion area was
exposed through a midline laparotomy. Aorta and celiac artery were isolated
and the ganglion was removed. For sham mice, the ganglion area was
exposed and aorta and celiac artery were isolated, without removing the
ganglion.
Splenectomy
Under isoflurane anesthesia (2–5 Vol%), supplemented with 1 L/min oxygen,
the abdominal cavity ofmice was opened and splenic vessels were cauterized.
The spleen was carefully removed. For control experiments, the abdomen was
opened as well, without spleen removal.
Generation of Chimeric Mice by Spleen Transplantation
The surgical procedure for spleen transplant was performed with some mod-
ifications, accordingly to the methodology of Swirski and colleagues (Swirski
et al., 2009). Briefly, donor mice were anesthetized with an intraperitoneal in-
jection of ketamine (90 mg/kg) and xylazine (10 mg/kg), followed by an intrave-
nous injection of heparin (Hospira). A longitudinal incision in the abdomen of
the donor allowed to the spleen. The aortic cuff connected to the splenic
artery, allowed vascular anastomosis of the spleen to the recipient. The recip-
ient mouse was anesthetized with isoflurane (2-5 Vol%) supplemented with 1
L/min oxygen. An abdominal midline incision was made to visualize the spleen
and vasculature. After isolation, the recipient splenic artery and vein were
clamped, then anastomosis among donor and recipient splenic veins and
arteries were created using 10.0 suture (Premilene, Braun) and clamp wasversus WT-veh; ###p < 0.001 versus WT-AngII (two-way ANOVA followed by Bo
showing PE-labeled CD86+ cells colocalize with PerCP-labeled CD68+ cells (gat
(D and E) Intrasplenic siRNA delivery for CD86 knocking down in WT mice. (D) Intr
aortas and kidneys after AngII infusion. n = 4 per group. *p < 0.05 versus WT-An
Ithen removed to restore blood flow. Mice were allowed to recover for at least
4 weeks and a fully restoration of blood supply, tissue oxygenation, and
regrowth of sympathetic nervous system innervation were controlled.
siRNA Injection
In mice anesthetized with ketamine-xylazine, after isolation of the splenic
artery and insertion of a micro medical tubing, Ambion In Vivo Pre-designed
siRNA Sirt1 (s96766) and siRNA CD86 (s63710) complexed with Invivofect-
amine 2.0 Reagent (18.75 nmol/dose) was delivered with a syringe pump
(WPI) at a constant infusion velocity. Control mice received an equal amount
of a siRNA targeted to luciferase (Sigma Aldrich) and Ambion In Vivo Neg
Control #1 siRNA, complexed with Invivofectamine 2.0 Reagent and delivered
with the same procedure. Mice received AngII (0.5 mg/kg/day) with osmotic
minipumps, at day 3 after siRNA delivery.
Blood-Pressure Measurements
Arterial blood pressure was monitored telemetrically, as previously described
(Brancaccio et al., 2003) by the HD–X11 pressure transmitters (Data Sciences
International) implanted in anesthetized mice with ketamine/xylazine. Radio
signals from the implanted transmitter were captured by the Physiotel RPC-
1 receiver (Data Sciences International), and the data were stored online using
the Dataquest Ponemah 4.9 acquisition system (Data Sciences International).
Conventional Blood Pressure Monitoring Was Held in Conscious
Mice with Tail-Cuff Plethysmography
In vivo acute pressure response study to AngII was conducted in anesthetized
mice with isoflurane. An arterial catheter was connected to a pressure trans-
ducer, MPVS ultra (Millar), and a venous catheter was used for drug injection.
Bolus injections of increasing doses of AngII (1–100 mg/kg) were administered
at least 2 min intervals. Dose response curves were established for the peak of
the BP responses.
Ultrasound Imaging
Ultrasound analysis was performed in mice anesthetized with tribromoethanol
(175 mg/kg), using Vevo 2100 device equipped with 18–38 MHz linear-array
transducer with a digital ultrasound system (Visualsonics), as previously
described (Carnevale et al., 2011).
Fluorescence Molecular Tomography–Computed Tomography
Imaging
Mice anesthetized with ketamine/xylazine were immobilized in a multimodal-
imaging cartridge, provided with fiducial marks on the frame that enable, after
acquisition of multiple imaging, the exact fusion of images with microCT. A
commercially available FMT system was used for in vivo imaging studies
(FMT1500, Perkin Elmer). 2 nmol per mouse of MMPsense 680 (Perkin Elmer)
were injected intravenously. Data were postprocessed using True Quant
software (Perkin Elmer) and FMT/CT DICOM images were fused with Amide
Medical Imaging Data Examiner Software, using fiducial points to define
X-Y-Z coordinates for both data sets.
Vascular Function Evaluation
Second-order mesenteric arteries were dissected out from anesthetized mice
and set up on wire myograph (DMT Instruments), in gassed KREBS, pH 7.4,
at 37C, under a normalized tension corresponding to an effective pressure
of 75 mmHg. Concentration-response curves were performed for PlGF and
phenylephrine and, then, with PlGF and ACh in vessels precontracted with
phenylephrine at 80% of KPSS contraction. All substances used were from
Sigma, except recombinant PlGF that was from R&D Systems.
ELISA for Determination of PlGF
PlGF levels were measured in triplicate for each sample, extracted with a
buffer containing PBS and protease inhibitor cocktail (Sigma), by a highnferroni’s post hoc test). Data are mean ± SEM. Representative plots in (C),
ed on total cells from the enriched population).
asplenic knockdown of CD86 in WT mice hampered the early T cells homing in
gII neg siRNA (unpaired t test). All data are shown as mean ± SEM.
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Results are expressed as pg/mg of total proteins, as measured by Bradford
Assay kit (Biorad).
ELISA for Determination of Noradrenalin
Noradrenalin levels were measured in duplicate for each sample, extracted
with a buffer containing 0.1N HCl and 1mM EDTA, by a high sensitivity ELISA
kit (IBL International), following manufacturer’s instructions. Results are
expressed as pg/g of weight tissue.
Isolation and Preparation of Single Cell Suspensions from Spleen,
Kidney and Aorta
Micewere anesthetizedwith ketamine/xylazine and spleenwas isolated. Then,
mice were exsanguinated and both kidneys and aorta were collected. Spleen
was mechanically disrupted and then passed through a 40 mm sterile filter
(Falcon, BD) and centrifuged at 3003 g for 10 min. After a treatment with
ACK Lysing Buffer (Lonza), the pellet was resuspended in PBS. Total splenic
leukocytes were stained and analyzed using flow cytometry or used to isolate
and enrich monocytes/macrophages by negative selection, using a commer-
cially available monocyte enrichment kit (EasySep Kit and Purple EasySep
Magnet, Stemcell Tech).
Kidney cell suspension was obtained disrupting mechanically two decapsu-
lated kidneys, and then passed through a 70 mm sterile filter (Falcon, BD). The
resulted cell suspension was centrifuged at 3003 g for 10 min. To isolate
lymphocytes from cell suspension, the pellet was then suspended in
36% Percoll (Sigma), gently overlaid onto 72% Percoll, and centrifuged at
1,0003 g for 30 min at RT.
Aorta cell suspension was obtained disrupting mechanically the tissue and
digesting the suspension in Digestion Cocktail, was then passed through a
70 mm sterile filter (Falcon, BD), and centrifuged at 3003 g for 5 min to pellet
the cells.
Before proceeding with stainings for flow-cytometric analyses, lymphocytes
from kidney and aorta total cells were enriched with Mouse T Lymphocyte
Enrichment Set-DM (BD IMag).
Samples were resuspended in PBS and then the number of the cells
was assessed using trypan blue and an automated counter (Countess, Life
Technologies).
Flow Cytometry Analysis
Splenic leukocytes (1 3 106), enriched monocytes (2 3 105), total kidney, and
aorta lymphocytes were preincubated with anti-CD16/32 Fc receptor and
then incubated with various combinations of mAbs, washed with PBS, centri-
fuged at 3003 g for 5 min at 4C, and resuspended in FACS buffer. Immu-
nofluorescence staining was analyzed using a C6 Accuri Flow Cytometer
and BD FACSCanto (BD Biosciences). The data were analyzed using FlowJo
Software.
Antibodies
The fluorochrome-conjugated mAbs to mouse antigens used for flow cytom-
etry analysis were as follows: anti-CD16/CD32 (2.4G2), PE anti-CD86 (GL1),
PE Isotype control Rat IgG2a, APC anti-CD11b (M1/70), PerCP-Cy5.5 anti-
CD8a (53-6.7), FITC anti-CD8a (53-6.7), APC anti-CD3e (145-2C11), PerCP
anti-CD45 (30-F11), FITC anti-CD4 (RM4-5), PE anti-CD4(RM4-5), APC anti-
CD69 (H1.2F3), APC-Cy7 anti-CD45 (30-F11), PE-Cy7 anti-CD44 (IM7) (BD
PharMingen), FITC anti-F4/80 (FA-11) (AbD Serotec), and PerCP-Cy5.5 anti-
CD68 (FA-11) (BioLegend).Figure 6. PlGF Repression of Macrophage Timp3 Is Crucial for AngII In
(A and B) Immunostaining of spleen from pre-HTN PlGF-deficient (indicated as
expression in CD68+ MZ macrophages, using anti-CD169 (A) and anti-CD68 (B)
(C) Immunostaining of spleen from pre-HTN MacT3 mice (and vehicle infused m
antibodies. Images are representative of n = 6 mice per group.
(D) Representative flow cytometric analyses in a fraction of monocytes/macroph
PerCP-labeled CD68+ cells from pre-HTN MacT3 versus WT mice (gated on tota
(E) Quantitative analysis showing percentage of CD86 expression in different frac
80+, and CD68+ cells. n = 6 per group. **p < 0.01 and ***p < 0.001WT-AngII versus
(repeated-measures two-way ANOVA followed by Bonferroni’s post hoc test). D
IChromatin Immunoprecipitation
Total splenocytes (2 3 107) were analyzed using Enzymatic Chromatin IP Kit
(Agarose Beads), as detailed by manufacturer’s instructions (Cell Signaling).
Briefly, anti-p53 1:500 antibody (Cell Signaling) was used for ChIP (10 mg of
crosslinked chromatin). The amount of Timp3 gene in the p53-immunoprecip-
itated chromatin was detected by PCR (Eppendorf Mastercycler) and normal-
ized with the total amount of the gene present in the 2% input of chromatin of
each immunoprecipitated sample.
Immunoblot
Splenocyte proteins were extracted with lysis buffer 1X (Cell Signaling) plus
1 mM phenylmethylsulfonyl fluoride (Sigma) and centrifuged at 14,0003 g
for 20 min. Total proteins were determined with Pierce BCA Protein Assay
Kit (Thermo Scientific). Proteins were resolved by SDS-PAGE followed by
immunoblotting using the following antibodies: rabbit anti-Sirt 1:500 (Milli-
pore), mouse anti-Gapdh 1:1000 (Santa Cruz). Secondary antibodies used
were: donkey anti-rabbit (1:5000) and goat anti-mouse (1:5000), from Santa
Cruz. Protein detection was performed with ECL kit (Amersham) and densi-
tometry was obtained with the Quantity One 1-D Analysis Software.
Histological Analysis, Immunohistochemistry, and
Immunofluorescence
Haematoxylin–eosin (H&E), Masson’s trichrome, and Picrosirius Red stainings
were performed according to standard procedures. Sections of kidney were
deparaffinized, rehydrated, and then underwent antigen retrieval. Vessels
were embedded in OCT (Leica Microsystems), postfixed with 4% paraformal-
dehyde for 15 min. Slides were processed for immunohistochemistry with the
following primary antibodies: anti-CD8 and anti-CD4 (1:50; BD PharMingen).
Appropriate biotinylated secondary antibodies (1:200; Vector) were used for
successive processing with DAB (Vector). Hematoxylin (Sigma) was used as
counterstaining. The number of CD8 and CD8-positive cells per mm2 was
determined using the Image J software Cell Counter plugin analysis tool.
For immunofluorescence analysis, 25 mm sections from spleen were post-
fixed with 4% paraformaldehyde for 15 min and processed for staining with
the following primary antibodies: rabbit anti-Timp3 (Novus biologicals) 1:500,
rabbit anti-PlGF (Abcam) 1:250, rabbit-anti CD86 (Novus Biologicals) 1:100,
rat anti-mouse CD68 (AbD Serotec) 1:200, rat anti mouse CD169 (AbD Sero-
tec) 1:100, Sheep-anti Tyrosine Hydroxylase (Millipore) 1:800, rat anti-mouse
CD45R (B220, BD PharMingen) 1:50, anti-hamster CD3 (BD PharMingen)
1:50, Rabbit anti-Sirt1 (Millipore) 1:250, and rat anti-ER-TR7 (Acris) 1:200.
Sections were then incubated with the respective secondary antibodies
conjugated to Alexa Fluor 488, Alexa Fluor 647 or Cy3. Slides were then cover-
slipped with DAPI containing medium (Vector). 25 mm sections were obtained
with cryostat microtome by celiac ganglion retrogradely labeled with Hydrox-
ystilbamidine methanesulfonate injected in the spleen and mounted and
coverslipped for analysis.
Confocal Microscopy Analysis
All coverslipped mounted tissue sections were scanned using a Zeiss 780
confocal laser scanning microscope with a Zeiss ECPLAN-NEOFLUAR 10x/
0.30 M27, ECPLAN-NEOFLUAR 20x/0.50 M27, ECPLAN-NEOFLUAR 403/
1.30 M27 oil immersion objective or PLAN-APOCHROMAT 633/1.4 oil DIC
oil immersion objective (Carl Zeiss Microimaging Inc.). We used a 405 Diode
laser to excite DAPI, a 488 nm argon laser to excite Alexa Fluor 488, and
a 543 HeNe laser to excite Cy3. Pseudocoloring was performed using ZEN
software (Carl Zeiss Microimaging).duction of CD86 and Hypertensive Response
PlGF KO) and WT mice (and respective vehicle infused mice), showing Timp3
antibodies. Images are representative of n = 6 experiments.
ice) as compared to WT mice, using anti-CD86 (green) and anti-CD169 (red)
ages enriched from total splenocytes. PE-labeled CD86+ cells colocalize with
l cells from the enriched population).
tions of monocytes/macrophages from the enriched population: CD11b+, F4/
WT-veh; ##p < 0.01 and ###p < 0.001MacT3 transgenic-AngII versusWT-AngII
ata are mean ± SEM.
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Figure 7. PlGF Exploits an Epigenetic Mechanism to Exert a Checkpoint of Immune System Activation in Hypertension
(A) BP response to chronic AngII in MacT3 transgenic and WT mice (and respective vehicle infused mice). n = 6 for AngII-treated groups and n = 4 for vehicle-
treated groups. Panels represent mean ± SEM values of SBP (left), DBP (middle), and MAP (right).
(B) Timp3 PCR in p53 ChIP (upper panels) and respective 2% input (lower panels) of chromatin of splenocytes from AngII-infused PlGF-deficient (indicated as
PlGF KO) and WT mice (and respective vehicle-infused mice). Images represent three independent experiments for each experimental group.
(C) Immunostaining showing Sirt1 (green) expression in splenic MZ, evidenced by CD169 staining (red), in AngII-infused PlGF KO and WT mice (and respective
vehicle-treated mice).
(D and E) BP response to chronic AngII, in PlGF KO mice treated with Sirt1 selective pharmacological inhibitor EX-527 (D) and genetic inhibition of splenic Sirt1
obtained by local in vivo infusion of a Sirt1 siRNA (E), as compared to a luciferase-targeted siRNA.
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All images were captured using a DMI3000B Leica optical microscope pro-
vided of Leica cameras (Leica Microsystems) and processed with the Leica
Application Suite (LAS V3.3).
Statistical Analysis
Data are presented as mean ± SEM. Statistical significance was calculated
accordingly to the experimental design, as indicated in the figure legends.
p < 0.05 was considered significant. Statistical analyses were performed
with GraphPad software PRISM5 (GraphPad Software).
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